Abstract

The process of preparing and enacting a biosafety law in Iran lasted more than a decade. This paper examines the process of biosafety policy-making in Iran in relation to the Cartagena Protocol on Biosafety (CPB) and to domestic Iranian factors. While some scholars argued that the CPB would be influential in developing countries, our findings indicate that it was not particularly important in Iranian biosafety legislation. This paper outlines the internal Iranian political processes, which initially envisaged a very precautionary approach, but which concluded with a biosafety law designed to promote the adoption of these technologies. Reference will be made to the changing influence of expert biotechnologists on policy-making. The dominance of domestic policy considerations, compared to CPB provisions, implies that signing the CPB does not imply that national regimes will converge on a common model, based on the text of the CPB.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call